Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC

This study has been completed.
Genentech, Inc.
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Duke University Identifier:
First received: August 24, 2005
Last updated: September 12, 2014
Last verified: October 2012